Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Disease-Modifying Antirheumatic Drugs in Children With Juvenile Idiopathic Arthritis

Slide: 43 of 46

Conclusions About Benefits and Adverse Effects of DMARDs (1 of 2)

Adding methotrexate to conventional care improves disease activity, as scored by physicians.
Strength of Evidence = Moderate

For children who respond to a biologic DMARD, continuing treatment reduces the risk of a flare.
Strength of Evidence = Moderate

Health status improves with treatment with both biologic and nonbiologic DMARDs, but statistically significant differences from controls are not consistent.
Strength of Evidence = Low